QRL-203 / QurAlis - LARVOL DELTA

QurAlis' FlexASOs Show High Potency and Improved Safety Over Standard ASOs (PRNewswire) - "QurAlis Corporation...today announced it will present new preclinical data showing the potential of the company's antisense oligonucleotides (ASOs) generated from its proprietary FlexASO™ Splice Modulator Platform. Data from two of QurAlis' FlexASO programs targeting rescue of STATHMIN-2 (STMN2) and UNC13A showed up to three-fold improvement over standard ASOs in both potency and biodistribution, and significantly reduced off-target effects, often from approximately 50 to 0, in human motor neurons. In addition, QurAlis' FlexASOs were not associated with cytokine or chemokine production. Observations from both programs therefore indicate that FlexASO™ technology results in a higher therapeutic index than observed with traditional ASO."

Preclinical • Amyotrophic Lateral Sclerosis • CNS Disorders